Table 3.
Comparison of COVID-19 anti-RBD and neutralising antibody before and after two doses of vaccination among different study groups.
| Type of Antibody | Prior Symptomatic Infection (Group A, n = 14) |
p-Value | Prior Asymptomatic Infection (Group B, n = 27) |
p-Value | No Prior Infection (Group C, n = 9) | p-Value | |||
|---|---|---|---|---|---|---|---|---|---|
| Before Vaccine | After Vaccine | Before Vaccine | After Vaccine | Before Vaccine | After Vaccine | ||||
| Anti-RBD antibody |
36.2 (2.4–88.7) |
3995 (1056–7748) |
<0.05 | 104.8 (14.0–208.1) |
4840 (1121–7874) |
<0.05 | 0.4 (0.4–0.4) |
29.2 (0.6–1143) |
<0.05 |
| Neutralising antibody |
40.5 (12.7–71.2) |
92.0 (75.6–93.2) |
<0.05 | 24.8 (19.8–52.0) |
92.0 (78.6–93.9) |
<0.05 | 7.2 (6.3–11.3) |
26.1 (14.4–67.0) |
<0.05 |
The titre of the anti-RBD antibody is expressed as U/mL, and neutralising antibody is expressed as %. The qualitative and quantitative data are expressed as number (proportion) and median (interquartile range).